Protocol Ledger

NCT05895786 · Phase III · RECRUITING

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Interventional Phase III clinical trial protocol NCT05895786 sponsored by Pfizer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-20 Enrollment: 318 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05895786
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)318 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05895786
Protocol FieldVerified Registry Value
NCT IdentifierNCT05895786
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment318 participants (ESTIMATED)
Registered Start Date2023-05-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI